A pair of drugs celebrated in anti-aging circles for clearing worn-out cells from the body has now been caught doing something nobody expected: stripping away the brain’s protective insulation in mice. The combination of dasatinib, a leukemia drug, and quercetin, a plant-derived flavonoid found in onions and berries, caused significant demyelination in the corpus callosum of both young and aged animals, according to a study published in the Proceedings of the National Academy of Sciences and reported on in May 2026.
The finding is jarring because the combination, commonly abbreviated D+Q, was being studied precisely to prevent the kind of cognitive decline it appears to produce. Rather than killing brain cells outright, the treatment forced oligodendrocytes, the specialized cells that wrap nerve fibers in myelin, to regress into an immature state. The result looked a lot like “chemo brain,” the fog of slowed thinking and impaired memory that cancer patients know all too well.
The insulation problem
Myelin is the fatty sheath that coats nerve fibers, functioning much like the plastic insulation around electrical wiring. Without it, signals between brain regions slow down, scatter, or fail entirely. The corpus callosum, the dense bridge of fibers connecting the brain’s left and right hemispheres, is one of the most heavily myelinated structures in the brain, and it is where the damage showed up.
Lead investigator Stephen Crocker of the University of Connecticut and his team found that oligodendrocytes exposed to D+Q did not die in large numbers. Instead, they lost the mature molecular characteristics needed to maintain myelin sheaths, effectively reverting to a juvenile form. That distinction matters: it means the damage follows a different biological path than the neurotoxicity caused by traditional chemotherapy drugs, even though the functional outcome (degraded white-matter integrity and impaired connectivity) overlaps with what chemo brain patients describe.
The PNAS paper also reported that the myelin damage appeared more pronounced in young mice than in aged ones, though the study did not provide a direct quantitative comparison between age groups on a single standardized metric. That observation undercuts any assumption that only older or already-vulnerable brains would be at risk, and it raises questions about the safety profile of D+Q across age groups.
Why D+Q had so much momentum
The combination earned its reputation through a string of promising preclinical results. Senescent cells, sometimes called “zombie cells,” accumulate with age and pump out inflammatory signals that damage surrounding tissue. Senolytics like D+Q are designed to selectively kill these cells, and in several mouse studies, the strategy appeared to work in the brain.
In one widely cited experiment using an Alzheimer’s disease mouse model, researchers reported that D+Q reduced senescence in oligodendrocyte progenitor cells and improved memory performance. That study also established that dasatinib could cross the blood-brain barrier, a critical prerequisite for any drug intended to act on the central nervous system. Separate work using both a genetic cell-ablation system and the D+Q cocktail showed that whole-body clearance of senescent cells dampened age-related brain inflammation and led to measurable cognitive improvements in mice.
Those results helped build a narrative that senolytics might rejuvenate the aging brain by pruning cells that had become chronically damaged and inflammatory. The enthusiasm was strong enough to push D+Q toward human neurological trials. A registered study on ClinicalTrials.gov lists the combination under evaluation for secondary progressive multiple sclerosis, a disease defined by progressive myelin loss, positioning D+Q as a potential therapy in a condition where preserving or restoring myelin is the central goal.
That collision between the drug’s intended use and its observed side effect in mice is the sharpest tension in the current evidence.
Critical gaps in the data
No human neuroimaging or biopsy data yet confirm whether D+Q produces comparable demyelination in people. The mouse findings, while striking, used a specific strain (C57BL/6J), route of administration, and dosing protocol that may not translate directly to the intermittent schedules typically proposed for human senolytic therapy.
The PNAS paper did not report washout or recovery timelines. Because oligodendrocytes regressed rather than died, recovery could theoretically occur once the drug pressure lifts, but no published data confirm that possibility or define how long such a recovery might take.
Direct measurements of drug concentrations in the brain during the demyelination experiments have not been separately reported. Earlier Alzheimer’s model work established that dasatinib crosses the blood-brain barrier, but the exact levels reached in the corpus callosum during the newer study remain uncharacterized. Without those numbers, it is difficult to gauge how closely the mouse exposure mirrors what human patients might experience.
There is also a monitoring gap on the clinical side. The ClinicalTrials.gov entry for the MS trial does not list demyelination or white-matter imaging as prespecified safety endpoints. Standard safety monitoring may catch serious neurological events, but subtle changes in myelin integrity or oligodendrocyte maturity could go unnoticed without targeted MRI sequences designed to detect them. Whether trial protocols will be updated in light of the new mouse data is not yet reflected in public records.
The paradox nobody has resolved
Adding another layer of complexity, a separate line of research published in Nature Communications found that D+Q could actually promote myelin repair after injury by clearing senescent-like microglia from the damage site. In that context, removing inflammatory cells appeared to reset the local environment and allow remyelination to proceed.
So the same drug combination can help rebuild myelin in one experimental setting and strip it away in another. The apparent contradiction has not been reconciled. Differences in dosing intensity, timing relative to injury, and which cell populations are targeted likely play a role, but the field has not yet produced a unified explanation that would let clinicians predict when D+Q will act as a helper and when it may act as a disruptor.
Neither set of results cancels the other. The brain is not a single-target organ, and a drug that clears harmful senescent cells in one compartment can simultaneously destabilize healthy mature cells in another. The earlier studies documenting cognitive benefits from D+Q in aging and disease contexts are real, peer-reviewed findings. So is the new demyelination data. Both are primary experimental evidence, and both demand attention.
Why off-label D+Q use for brain health lacks support
For researchers, clinicians, and the growing number of people who have experimented with D+Q as a longevity supplement, the current evidence argues for a hard pause on assumptions. In mice, D+Q can both improve cognition by clearing senescent cells and impair white matter by destabilizing oligodendrocytes, depending on context. In humans, the balance between those effects is unknown.
Until targeted safety data from neurological trials become available, off-label or consumer use of D+Q for brain health rests on an incomplete and internally conflicted preclinical record. The same mechanism that promises rejuvenation may, under certain conditions, erode the very insulation that keeps neural circuits running smoothly. That is not a reason to dismiss senolytics as a field, but it is a reason to stop treating D+Q as a proven brain tonic. The mice made that much clear.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
